timothy sykes logo
RXRX Stock Steadies As Insider Activity Draws Trader Focus Thumbnail
G Google News

RXRX Stock Steadies As Insider Activity Draws Trader Focus

JACK KELLOGG•UPDATED SEP. 18, 2026, 3:02 PM ET
Reviewed by Tim Sykesand Fact-checked by Ellis Hobbs

Recursion Pharmaceuticals Inc. stocks have been trading up by 4.52 percent after positive AI-driven drug discovery partnership news.

Key Takeaways

  • Recent Form 4 filings show insider changes in RXRX beneficial ownership, putting Recursion Pharmaceuticals Inc. back on trader watchlists.
  • Regulatory disclosures give traders a fresh data point just as RXRX consolidates above $3.50 after a choppy stretch.
  • Heavy losses and negative margins remain a key overhang, even with strong cash reserves and low debt.
  • Short-term charts show tight intraday ranges, favoring disciplined scalpers over breakout chasers.

Candlestick Chart

Live Update At 15:02:14 EDT: On Friday, September 18, 2026 Recursion Pharmaceuticals Inc. stock [NASDAQ: RXRX] is trending up by 4.52%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

RXRX is acting like a classic high-burn, high-upside biotech platform name. On the income side, Recursion Pharmaceuticals Inc. printed about $7.3M in quarterly revenue, but that barely dents its spending. RXRX reported a net loss of roughly $131M for the latest quarter, with EBITDA near -$112.5M. Those numbers tell traders this is still a long-duration story, not a cash machine.

Margins confirm it. RXRX shows gross margin near 2.9% and brutal negative profit margins, which is normal for a drug discovery platform still in scaling mode but crucial for risk management. The company leans heavily on its balance sheet to stay in the game.

That balance sheet is the bright spot. RXRX holds about $545.7M in cash and equivalents and total assets around $1.21B, with total liabilities under $300M and long-term debt near $4.8M. Current ratio around 5 and quick ratio about 4.6 give Recursion Pharmaceuticals Inc. real runway.

More Breaking News

On the chart, RXRX has been grinding between roughly $3.20 and $3.70, with recent closes near $3.70. For traders, that combination—big losses, big cash, tight range—screams “trade the levels, not the story.”

Why Traders Are Watching Insider Filings

RXRX just dropped a new insider Form 4 on 2026/09/16, disclosing changes in beneficial ownership at Recursion Pharmaceuticals Inc. Two earlier Form 4 notes—on 2026/09/02 and 2026/09/10—show a pattern: insiders at RXRX are active, even if the public filings don’t spell out size, price, or whether it was a buy or a sale.

For traders, the exact direction matters less than the fact that insiders are moving at all. When Recursion Pharmaceuticals Inc. insiders touch stock, it often lines up with shifts in sentiment, liquidity, or upcoming catalysts. RXRX is already a heavily watched AI‑driven drug discovery name; add insider activity and you have a new storyline for short-term trading.

Now tie that to the tape. Over the last few weeks, RXRX has climbed from closes around $3.20–$3.30 to $3.70, holding higher lows along the way. The intraday five‑minute chart shows RXRX spending much of the day between $3.65 and $3.71, with very tight candles and controlled volatility. That kind of action signals accumulation or balanced supply and demand.

Traders in the Sykes community focus on exactly this setup: a beaten‑down story stock like Recursion Pharmaceuticals Inc., stabilizing on the daily chart, with a fresh insider headline to attract volume. The edge isn’t in predicting where RXRX will be in a year; it’s in understanding how these filings can spark short squeezes, morning spikes, or failed breakouts in the next few days. RXRX is now a tactical ticker, not background noise.

Conclusion

RXRX sits at an interesting crossroads. Recursion Pharmaceuticals Inc. is burning over $100M in free cash flow per quarter, posting heavy negative returns on assets and equity. Yet RXRX also holds more than half a billion dollars in cash, minimal long‑term debt, and a sizable asset base built around its AI‑driven drug discovery platform. That’s the tension every RXRX trader is really trading: time versus cash.

The insider Form 4 activity adds a new layer. When Recursion Pharmaceuticals Inc. insiders adjust beneficial ownership, savvy traders don’t assume bullish or bearish automatically. They track how RXRX reacts around support and resistance, watch volume, and then react to price, not headlines alone.

RXRX’s recent grind from low $3s to about $3.70 shows that buyers are at least defending this zone, even with ugly margins. Short-term, RXRX offers clear intraday levels and a defined range—fertile ground for disciplined day trading and swing trading. In choppy, news‑driven names like this, sticking to small, consistent wins can be far more sustainable than swinging for home runs on every trade—As millionaire penny stock trader and teacher Tim Sykes, says, “Small gains add up over time; focus on building wealth gradually, not chasing jackpots.” That mindset aligns well with trading a volatile ticker like RXRX, where tight risk management and realistic expectations matter.

As Tim Sykes likes to say, “The market doesn’t care about your opinion, only your discipline.” For RXRX, that means respecting risk, cutting losses quickly, and letting the chart—not the hype around Recursion Pharmaceuticals Inc.—dictate your next move. This coverage is for educational and research purposes only, and traders should always do their own due diligence before trading RXRX.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”